Aethlon Medical Bilan de santé

Santé financière contrôle des critères 4/6

Aethlon Medical possède un total de capitaux propres de $6.0M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $8.8M et de $2.8M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$6.86m
Fonds propres	US$6.02m
Total du passif	US$2.83m
Total des actifs	US$8.85m

Mises à jour récentes de la santé financière

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de EJU0 ( $7.1M ) dépassent ses passifs à court terme ( $2.3M ).

Passif à long terme: Les actifs à court terme de EJU0 ( $7.1M ) dépassent ses passifs à long terme ( $496.8K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: EJU0 est sans dette.

Réduire la dette: EJU0 n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: EJU0 dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: EJU0 dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 17.3 % chaque année

Aethlon Medical Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Aethlon Medical Receives Non-Compliance Notice of Delisting from Nasdaq

Recent updates

New major risk - Revenue and earnings growth

Aethlon Medical Announces Enrollment of the First Patient in (FPI) Its Hemopurifier Cancer Trial in Australia

Aethlon Medical, Inc. to Report Q2, 2025 Results on Nov 13, 2024

Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier Cancer Trial in India

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial

Aethlon Medical, Inc. Announces Publication of Preclinical Data Showing Ability of the Hemopurifier to Remove Extracellular Vesicles and MicroRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Donor Kidneys

Aethlon Medical, Inc., Annual General Meeting, Sep 27, 2024

Aethlon Medical, Inc. Receives Second Ethics Committee Approval for Hemopurifier Cancer Trial

Aethlon Medical, Inc. to Report Q1, 2025 Results on Aug 14, 2024

Aethlon Medical, Inc. to Report Fiscal Year 2024 Results on Jun 27, 2024

Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier® Cancer Trial

Aethlon Medical, Inc. Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies

New major risk - Shareholder dilution

Aethlon Medical, Inc. has completed a Follow-on Equity Offering in the amount of $4.69235 million.

Aethlon Medical, Inc. Reports Positive Results from an In Vitro Binding Study of Its Hemopurifier in Removing Extracellular Vesicles from Cancer Patient Plasma

Aethlon Medical, Inc. has filed a Follow-on Equity Offering in the amount of $16.32 million.

Aethlon Medical, Inc. to Report Q3, 2024 Results on Feb 14, 2024

New major risk - Financial position

Aethlon Medical, Inc. Announces Appointment Ofguy Ciprian as Chief Operating Officer

Aethlon Medical, Inc. to Report Q2, 2024 Results on Nov 14, 2023

Aethlon Medical, Inc. Receives Clearance from Drug Controller General of India for Potential Phase 1 Trial of its Hemopurifier(R) in Oncology

Aethlon Medical, Inc. to Report Q1, 2024 Results on Aug 10, 2023

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2023

Aethlon Medical, Inc. Appoints Nicolas Gikakis as Member of the Board and Member of the Nominating Committee

New major risk - Shareholder dilution

Full year 2023 earnings released: US$0.59 loss per share (vs US$0.71 loss in FY 2022)

Aethlon Medical, Inc. to Report Q4, 2023 Results on Jun 28, 2023

No longer forecast to breakeven

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.16 loss in 3Q 2022)

Aethlon Medical, Inc. to Report Q3, 2023 Results on Feb 13, 2023

Forecast to breakeven in 2023

No longer forecast to breakeven

First half 2023 earnings released: US$0.37 loss per share (vs US$0.29 loss in 1H 2022)

Aethlon Medical, Inc. to Report Q2, 2023 Results on Nov 14, 2022

Aethlon Medical Receives Non-Compliance Notice of Delisting from Nasdaq

Aethlon Medical, Inc. Announces Early Feasibility Study of the Hemopurifier

Forecast to breakeven in 2023

Aethlon Medical, Inc. to Report Q1, 2023 Results on Aug 09, 2022

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2022

Aethlon Medical, Inc. Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment

Aethlon Medical, Inc. to Report Fiscal Year 2022 Results on Jun 28, 2022

Insufficient new directors

Aethlon Medical, Inc. Announces Executive Changes

Aethlon Medical, Inc. to Report Q3, 2022 Results on Feb 14, 2022

Insufficient new directors

Full year 2021 earnings released: US$0.65 loss per share (vs US$1.87 loss in FY 2020)

Aethlon Medical, Inc. Publishes Case Studies of Two Critically ill Covid-19 Patients Treated with the Hemopurifier®

Forecast to breakeven in 2023

Third quarter 2021 earnings released: US$0.20 loss per share (vs US$0.28 loss in 3Q 2020)

Revenue beats expectations

New 90-day high: €2.30

Aethlon Medical, Inc. to Report Q3, 2021 Results on Feb 10, 2021

Aethlon Medical, Inc. Announces Executive Appointments

New 90-day high: €2.10

Aethlon Medical, Inc. Announces First Patient Treated in First-in-Human Clinical Trial of HEMOPURIFIER® in Head and Neck Cancer

New 90-day high: €1.94

New 90-day high: €1.49

Aethlon Medical, Inc. Announces Board Changes, Effective as of October 30, 2020

Aethlon Medical, Inc. Announces Executive Changes, Effective as of October 30, 2020

Aethlon Medical, Inc. to Report Q2, 2021 Results on Oct 28, 2020

New 90-day low - €1.11

First quarter earnings released

Aethlon Medical, Inc. to Report Q1, 2021 Results on Aug 11, 2020

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines